Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT05617885 · Praful Ravi, MB BCHir, MRCP · PHASE1 · terminated · last registry update 2026-10-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.” | – | Registry record, Praful Ravi, MB BCHir, MRCP |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Results posted on the registry: Alliance Foundation Trials, LLC., Apalutamide + LHRH Analogue (NCT03009981)
- 2026-10-27Phase 3 first posted: Amneal Pharmaceuticals, LLC, Testosterone Cypionate 75 mg + Testosterone cypionate 50 mg (NCT07898072)
- 2026-10-27Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-27Also stopped (terminated): National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-21Phase 3 first posted: Khyber Medical University Peshawar, Thalidomide + Danazol (NCT07884773)
- 2026-10-02Also stopped (withdrawn): Tulane University, XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector (NCT04601233)
- 2026-10-01Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Abiraterone Acetate + Cabazitaxel (NCT07852195)
- 2026-09-29Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Testosterone Undecanoate + Enzalutamide (NCT05081193)
- 2026-09-17Also stopped (terminated): Jefferson Drapkin, Vaginal Cream with Applicator (NCT04807894)
- 2026-09-02Results posted on the registry: University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-09-02Also stopped (terminated): University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-08-03Phase 3 first posted: VA Office of Research and Development, testosterone cypionate + finasteride (NCT07742553)
- 2026-07-16Results posted on the registry: Dana-Farber Cancer Institute, Testosterone Cypionate 100 MG/ML + Placebo (NCT03716739)
- 2026-07-02Results posted on the registry: Washington University School of Medicine, Androgen deprivation therapy (NCT05628363)
- 2026-05-07Results posted on the registry: Brigham and Women's Hospital, Testosterone Undecanoate (NCT03576001)
- 2026-05-07Also stopped (terminated): University of Southern California, Oxandrolone + Placebo (NCT03091075)
- 2026-03-27Also stopped (suspended): George F. Hatch, Oxandrolone + Placebo (NCT05893069)
- 2025-12-23Results posted on the registry: VA Office of Research and Development, Testosterone gel 1.62% + Placebo (NCT03887936)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision